Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-312 first-line tarlatamab plus durvalumab and platinum-etoposide in extensive-stage small cell lung cancer
MOH_2025-09-18_014351Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoint: Overall survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2025-09-18_014351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-18_014351.